Effective gene therapy for disseminated metastatic cancer is currently impossible because of poor delivery of vector to target sites. Modification of viral vectors to target advanced cancer has long been a challenge. In this study, we aimed to redirect adenovirus tropism to infect prostate cancer cells via a6b1 integrins, whose expression is upregulated during prostate cancer progression. To ablate normal mechanisms of infection and provide a framework for attachment of targeting ligands, viruses were non-genetically modified with pHPMA-ONp polymer. Addition of polymer-coated virus to prostate cells showed significantly reduced transgene expression compared with unmodified virus. To restore infectivity, an a6-integrin binding peptide (-SIKVAV-) derived from laminin was incorporated onto the surface of the polymer-coated viruses. Photon correlation spectroscopic analysis revealed a small increase in the mean diameter of the particles following retargeting. Addition of -SIKVAV-peptide restored virus infectivity of PC-3 cells in a ligand concentration-dependent manner that was significantly improved following removal of unincorporated polymer and peptide. Competition assays using cells preincubated with Ad5 fiber protein or free -SIKVAV-peptide confirmed that entry of retargeted viruses was mediated via the incorporated ligand. Application of retargeted viruses to a panel of human cell lines revealed varying levels of transduction efficiency. Flow cytometric analysis of cells using anti-a6 integrin and anti-b1 integrin antibodies demonstrated that for prostate cells, greater transduction efficiency correlated with higher levels of expression of both integrin subunits. Furthermore with the exception of LNCaP cells, increased a6b1 integrin expression correlated with advanced disease. Intravenous administration of retargeted viruses to tumor-bearing mice resulted in slower plasma clearance and greatly reduced liver tropism, and hence toxicity compared with unmodified virus, while maintaining reporter gene expression in the tumor. The data suggest that YESIKVAVS-retargeted viruses have potential for systemic delivery for the treatment of metastatic disease.
Introduction
In 2002, cancer was responsible for around 40% of early deaths in the UK (www.cancerresearchuk.org). Metastasis of tumor cells to distant organs is the main cause of mortality, a process requiring several translocation steps, including detachment from the primary tumor mass, intravasation, adhesion to vessel walls, extravasation and infiltration into the new site. Many of the cell:cell and cell:matrix interactions involved in this process are mediated by integrins, a diverse family of noncovalently-associated ab heterodimer transmembrane receptors.
Gene therapy for disseminated cancer is currently prohibited by poor delivery of the vector to the target site. Curiel and co-workers have employed genetically modified adenoviruses displaying integrin targeting RGD motifs located within the fiber structures. These a v b 3 and a v b 5 integrin binding viruses show improved gene delivery efficiency in various CAR deficient cell lines; however, when delivered intravenously to mice, the majority of input dose is removed from circulation by uptake into the liver. 1, 2 Vectors targeted to infect cells via integrins that are selectively expressed on metastatic tumor cells is an interesting option and the primary focus of this study.
To date, 18 a and eight b integrin chains have been identified in vertebrates. 3, 4 The a6-subfamily of integrins are key mediators of cellular interactions with their environment, forming heterodimers with b4 (associated with stable hemidesmosomes and cell-cell adherence) or b1 (involved in the formation of dynamic focal contacts for cell locomotion). In addition, a6 (CD49f) and b1 (CD29) integrins have recently been shown to be stem cell markers being highly expressed on mammary epithelial stem cells. 5, 6 Expression of a6b1 and a6b4 integrins is frequently altered in tumor cells [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] with reduction in b4 subunit expression leading to increased a6b1 integrin heterodimerization and consequently increased migratory and invasive properties. 11, 20, 21 During prostate cancer progression, the expression of the b4 subunit, detectable in normal basal epithelial cells and prostatic intraepithelial neoplasia lesions, is lost leading to a loss of hemidesmosomes in highly metastatic prostate carcinoma cells. 15, 22 The a6b1 integrin therefore provides an intriguing target for selective gene delivery to metastatic prostate cancer, provided an appropriate targeting ligand can be identified. Both a6b1 and a6b4 integrins are thought to bind primarily to laminin, specifically the elastasegenerated E8 fragment of the laminin a1 chain. 4 Tashiro et al. 23 identified the peptide sequence IKVAV located within the E8 region that promoted cell adhesion, spreading and neurite outgrowth. SIKVAV mediated urokinase-type plasminogen activator (uPa) expression in macrophages 24 and mast cell adherence to a SIKVAV containing peptide 25 can both be blocked using monoclonal antibodies directed against the a6 integrin subunit.
Non-genetic targeting of adenovirus with specific ligands can be readily achieved using a covalent coating strategy we have previously developed. Virus particles are first coated with a multivalent reactive polymer based on N[2-(hydroxypropyl)methacrylamide]
(pHPMA-ONp) that occludes virus surface proteins and blocks receptormediated uptake pathways. 26 Covalent linkage of the new ligand to the surface of the tropism-ablated vector restores transgene expression mediated through specific receptors. We have pursued this strategy in this study, using the retargeting ligand YESIKVAVS to mediate specific binding and infection of metastatic cancer cells through a6b1 integrins.
The addition of YESIKVAVS to polymer-coated adenovirus restored much of the transduction capability ablated by the polymer modification in a ligand concentration-dependent manner. Competition studies confirmed that uptake was mediated by incorporated ligand and was CAR-independent. Application of retargeted viruses to a panel of prostate cell lines demonstrated enhanced infection of cells derived from metastatic cancers that was related to the expression of a6 integrins. Intravenous administration of YESIKVAVS-retargeted polymer-coated virus to tumor-bearing mice showed highly efficient de-targeting of the liver, and hence greatly reduced toxicity while maintaining tumor tropism. The data suggest that this system provides the basis for systemic tumor targeting.
Materials and methods

Cells
PC-3 human prostate adenocarcinoma (bone metastasis) (ECACC No. 90112714), PNT1a and PNT2-C2 normal human prostate glandular epithelial cells immortalized with SV40, [27] [28] [29] and 293 adenovirus transformed human embryo kidney cells (ATCC No. CRL-1573), were each maintained in Dulbecco's minimal essential medium (DMEM), 10% foetal calf serum (FCS), 2 mM glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (Invitrogen, Paisley, UK). LNCaP human prostate carcinoma (supraclavicular lymph node metastasis) cells (ECACC No. 89110211) were maintained in RPMI 1640 medium, 10% FCS, 2 mM glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (Invitrogen, Paisley, UK). MCF-7 human breast adenocarcinoma cells (ATCC No. HTB-22) were maintained in minimal essential medium (MEM) with Earle's salts, 10% FCS, 2 mM glutamine, 1.0 mM sodium pyruvate, 0.1 mM non-essential amino acids, 1.5 g/l sodium bicarbonate, 0.01 mg/ml bovine insulin, 50 U/ml penicillin, 50 mg/ml streptomycin. P4E6 an immortalized human prostate epithelial cell line derived from a welldifferentiated tumor representing a model of early prostate cancer, 30, 31 was maintained in keratinocyteserum free medium (SFM) medium, 10% FCS, 2 mM glutamine, 5 ng/ml epidermal growth factor human recombinant and 50 mg/ml bovine pituitary extract (Invitrogen, Paisley, UK).
Viruses
Adluc (E1, E3 deleted expressing CMV IE driven luciferase) was grown in 293 cells until a cytopathic effect was observed. Virus was released from cells by freeze/ thawing, extracted with N-butanol and double banded on a CsCl gradient. The virus was treated with 0.15 U/ml benzonase (Merck Biosciences, Nottingham, UK) to remove free DNA and dialyzed into phosphate-buffered saline (PBS) containing 50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES), 0.1 g/l Mg and Ca, 10% glycerol pH 7.8 (HEPES containing phosphate buffered saline (HPBS) storage buffer). Particle numbers were estimated using the pico green assay (Molecular Probes, Paisley, UK) in which 1 mg/ml DNA ¼ 2.7 Â 10 10 particles/ml. 32 Infectivity was measured by plaque assay in 293 cells in which particle: infectivity ratios of 50-200 were obtained.
Ad5 fiber protein was purified from soluble antigen (SA) obtained from CsCl centrifugation gradients, initially using a DEAE Sepharose column (Amersham Biosciences, Buckinghamshire, UK) and subsequently using a Mono Q anion exchange column (Amersham Biosciences, Buckinghamshire, UK). Separated protein peaks were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and analyzed by Western blot using a guinea-pig anti-fiber antiserum 33 Virus modification pHPMA-ONp, a random copolymer formed from monomers of N-(2-hydroxypropyl)methacrylamide (90 mol%) and methacryloyl-Gly-Gly-4-nitrophenoxy ester (10 mol%) weight average of 22 000, was prepared by Polymer Labs (UK). pHPMA-ONp (10 ml) (re-suspended in sterile distilled water at 60, 90 or 120 mg/ml) was reacted with 50 ml Adluc (1 Â 10 11 -1 Â 10 12 particles/ml) in HPBS (PBS containing 50 mM HEPES, pH8.0) at room temperature for 1 h and then 41C overnight. Initially, Adluc was retargeted with the YESIKVAVS peptide bearing a PEG spacer in the absence of further purification. Briefly, virus was reacted with pHPMA-ONp at a final concentration of 15 mg/ml for 1 h and mixed with 50, 100, 500, 1000 or 2000 mg/ml YESIKVAVS-PEG in HPBS on ice overnight. Purified virus was prepared by reacting Adluc with pHPMA-ONp for 1 h as described above and free polymer was removed using a Sepharose S-400 spin column (Amersham Biosciences, Buckinghamshire, UK), according to the manufacturer's instructions. Optimum salt and pH conditions were re-established by adding 4 ml 20 Â HPBS pH 8.0, before mixing with YESIKVAVS-PEG at a final concentration of 500 mg/ml and incubating on ice overnight. Unincorporated ligand was removed using a Microcon 50000 MW filter device (Millipore, UK). Non-retargeted polymer-coated virus was also incubated on ice overnight to hydrolyze remaining ester groups. Following purification, virus recovery was determined by pico green assay. To eliminate the possibility of nonspecific peptide interactions mediating increased virus cell binding, a scrambled version of the peptide (IVV-SYAKSE) was synthesized and PEGylated (Severn Biotech, Kidderminster, UK). The scrambled peptide was reacted with polymer-coated Adluc as described above.
Assessment of relative particle size by photon correlation spectroscopy The physical size and polydispersity of unmodified, polymer-coated and YESIKVAVS-retargeted viruses were measured by dynamic light scattering using a Zetasizer 3000 (Malvern Instruments, Malvern, UK) equipped with a 50-mW internal laser. At least 10 measurements were obtained for each sample at 251C in HPBS at a scattering angle of 901 and analyzed by monomodal analysis. The machine was calibrated using 199 nm (76 nm) polymer beads (Duke Scientific Corp., Freemont, CA, USA).
Virus transduction assays 5 Â 10 4 cells were seeded into the wells of a 24-well plate, 24 h before the addition of 1.5 Â 10 7. unmodified, polymercoated or retargeted virus particles (300 particles/cell) in 100 ml of infection medium (DMEM, 2% FCS, 2 mM glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin). The medium was removed after 90 min, the cells briefly rinsed with PBS and 1 ml of fresh medium (DMEM, 10% FCS, 2 mM glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin) added. Competition assays were performed by preincubating cells for 1 h with 50 mg/ml of adenovirus fiber protein or 500 mg/ml YESIKVAVS-PEG peptide before the addition of virus. Luciferase expression was determined after 48 h using the Promega luciferase assay kit and a Lumat LB9507 luminometer (Berthold Technologies, Huddersfield, UK). The amount of protein in each cell lysate was determined using the Advance protein assay (Cytoskeleton, Denver, CO, USA) and luciferase expression standardized for protein content (error bars are shown as s.e.m.). These data were analyzed using unpaired t-tests.
In vivo pharmacokinetics and transgene expression MF-1 nude mice were implanted with 5 Â 10 6 PC-3 cells by subcutaneous injection and tumors allowed to establish for several weeks. Twenty-four hours before virus administration, mice were treated with 200 ml clodronate liposomes (clodronateliposomes.org) by i.v. injection to deplete the resident macrophages in the liver (Kupffer cells) and spleen. 2.5 Â 10 10 Adluc, pcAdluc or YESIK-VAVS-pcAdluc particles were administered in 100 ml PBS/ glycerol by tail vein injection. Twenty microliters of blood samples were taken at 2, 10, 30 min and 48 h after virus administration and diluted to a final volume of 200 ml in PBS. RBCs were pelleted and the plasma was removed to a separate vial with RBCs resuspended in 200 ml of fresh PBS. Viral DNA from RBC and plasma samples was extracted using a GenElute Mammalian Genomic DNA kit (Sigma-Aldrich, Gillingham, UK), according to the manufacturer's instructions.
Mice were killed after 48 h and the organs (liver, lungs, heart, kidneys, spleen and tumor) were harvested, weighed and homogenized in PBS at 300 mg tissue/ml (Ultra Thurax T25 Homogeniser). Tissue homogenate was analyzed for luciferase activity using Luciferase assay kit (Promega, Southampton, UK) as described above.
The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum after 48 h were determined by sample incubation at 371C in a UV spectrometer with Infinity ALT or AST reagent (Thermo Electron Corporation, Waltham, MA, USA) and monitoring the change in absorbance at 340 nm.
Quantitative polymerase chain reaction Quantitative Polymerase-chain reaction was performed using adenovirus fiber knob-turn junction forward primer 5 0 -TGG CTG TTA AAG GCA GTT TGG-3 0 , reverse primer 5 0 -GCA CTC CAT TTT CGT CAA ATC TT-3 0 and probe 5 0 -TCCAATATCTGGAACAGTTCAAA GTGCTCATCT-3 0 labelled with FAM and TAMRA. DNA was amplified using the thermal cycling conditions, 501C for 2 min, 951C for 10 min, followed by 40 cycles of 951C for 15 s and 601C for 1 min, generated in an Applied Biosystems 7000 Sequence Detection System. Subsequent analysis was performed using ABI Prism 7000 SDS Software. A standard curve for each virus (Adluc, pcAdluc and YESIKVAVS-pcAdluc) was generated by 10-fold dilutions in PBS; however, no significant differences between viruses were observed.
Results
Physical characterization of YESIKVAVS-pcAdluc
The YESIKVAVS peptide was linked via the C terminal to a PEG spacer to reduce steric hindrance following attachment to polymer-coated virus (Severn Biotech, Kidderminster, UK). The successful reaction of YESIK-VAVS-PEG with pHPMA-ONp polymer was monitored by release of paranitrophenol into solution (data not shown).
To determine the effect of polymer modification and peptide attachment on the physical properties of Ad5; unmodified (Adluc), polymer-coated (pcAdluc) or peptide-retargeted (YESIKVAVS-pcAdluc) viruses were analyzed by photon correlation spectroscopy. The mean virus diameter increased by 5 nm following reaction with 15 mg/ml pHPMA-ONp, whereas attachment of YESIKVAVS-PEG increased the diameter to 130 nm (Figure 1a) . The polydispersity (the width of the particle size distribution) was only marginally greater after modification (Figure 1b) , indicating that viruses remained relatively homogenous. Consequently, we would not expect modification to cause physical entrapment in capillary beds following intravenous administration.
Reaction of Adluc with pHPMA-ONp substantially attenuates transduction
The ability of pHPMA-ONp polymer coating to inhibit Adluc transduction was examined using LNCaP, PC-3 and MCF-7 cells (Figure 2) . Unmodified virus transduced the three cell lines with an efficiency that correlated with cell surface expression of the primary adenovirus receptor CAR ( Table 1 ), such that luciferase expression was 10-fold higher in LNCaP cells than MCF-7 cells. Transgene expression from polymer-coated virus was substantially reduced in each cell line, the degree of attenuation increasing with polymer concentration (Figure 2 ).
Incorporation of YESIKVAVS restores transduction activity of polymer-modified virus
To determine whether YESIKVAVS peptide incorporation could restore the ability of polymer-modified virus to transduce cells, transgene expression in PC-3 cells was examined following incubation with Adluc, pcAdluc or YESIKVAVS-pcAdluc at 300 particles/cell. Polymermodified virus was reacted with increasing amounts of YESIKVAVS-PEG to assess the effect of ligand concentration on transduction. pcAdluc-treated cells generated 8500-fold lower luciferase expression than Adluc-treated cells (P ¼ 0.0006) (Figure 3a) . In contrast, cells transduced with YESIKVAVS-pcAdluc expressed significantly greater levels of luciferase in a ligand concentration-dependent manner. The greatest transgene expression was from virus modified with 1 mg/ml YESIKVAVS-PEG, the level of luciferase activity being 900-fold greater than pcAdluc (P ¼ 0.0014). Further increases in peptide concentration (2 mg/ml) generated lower expression presumably because of increased competition from unincorporated peptide for receptor binding. Addition of YESIKVAVS-PEG to cells transduced with Adluc or pcAdluc had no effect on luciferase expression (data not shown).
We reasoned that the removal of unincorporated polymer and peptide from YESIKVAVS-pcAdluc would improve transduction. pcAdluc was thus passed through a Sepharose S-400 spin column removing approximately 99% of free pHPMA-ONp (data not shown). Following reaction with 500 mg/ml YESIKVAVS-PEG, unincorporated peptide was removed using a 50 000 MW cutoff spin column (Millipore, UK). Purification increased luciferase expression from YESIKVAVS-pcAdluc transduced cells by 16-fold (Figure 3b ).
YESIKVAVS-pcAdluc transduces PC-3 cells in a CAR-independent/ligand-dependent manner
To determine whether YESIKVAVS-pcAdluc-mediated transduction was independent of CAR; cells were preincubated with 50 mg/ml adenovirus fiber protein before the addition of virus. Luciferase activity from Adluc fell by 87% in LNCaP cells (data not shown) and 30% in PC-3 cells (Figure 4a ) in the presence of fiber protein, consistent with decreased viral uptake because of reduced CAR availability. The addition of fiber had no effect on the transduction of MCF-7 cells that lack CAR (data not shown). In contrast, the level of transgene expression from YESIKVAVS-pcAdluc in PC-3 cells was unaffected in the presence of fiber, confirming virus uptake was no longer mediated by initial CAR binding (Figure 4b) .
To confirm that the attached ligand was mediating uptake, PC-3 cells were preincubated with 500 mg/ml YESIKVAVS-PEG before the addition of YESIKVAVSpcAdluc, resulting in a small but significant reduction (P ¼ 0.0466) in transgene expression (Figure 4c ).
To determine whether the incorporated peptide was restoring transduction capability in a sequence-specific manner, a scrambled peptide IVVSYAKSE was synthesized and PEGylated at the C terminus. Addition of the scrambled peptide to polymer-coated virus failed to restore virus transduction (data not shown), confirming that cell interactions were sequence specific.
Retargeting Adluc via YESIKVAVS in prostate cells is mediated by a6b1 integrin expression YESIKVAVS contains the IKVAV sequence from the laminin a1 chain with a6b1 integrin binding activity. To determine whether YESIKVAVS-pcAdluc transduction was specific to cells expressing a6b1 integrins, viruses were applied to a range of human epithelial cell lines. YESIKVAVS incorporation mediated restoration of reporter gene expression only in the cell lines derived 
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Adluc pc10 pc15 pc20 mock Adluc pc10 pc15 pc20 mock Adluc pc10 pc15 pc20 mock Figure 2 Polymer coating of Adluc reduced transduction of PC-3, LNCaP and MCF-7 cells. To assess the effect of increasing polymer concentration, Adluc was reacted with pHPMA-ONp at 10 mg/ml (pc10), 15 mg/ml (pc15) or 20 mg/ml (pc20). Cells were incubated with Adluc or pcAdluc at 300 particles/cell for 90 min and luciferase activity determined after 48 h. Readings were adjusted for protein content whereas error bars indicate the s.e.m. Data are shown as the percentage number of immunopositive cells and the relative expression level (area under the curve) determined by multiplying the fraction of positive cells by the mean fluorescent intensity.
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SIKVAV retargeting of polymer-coated Ad M Stevenson et al from metastatic or well-differentiated tumors. Infection of PC-3, MCF-7 and P4E6 cells with YESIKVAVS-pcAdluc showed significant increases in transgene expression compared with pcAdluc, whereas in LNCaP, PNT1a and PNT-2 cells there was little or no difference (Figure 5a ). The pattern of a6 and b1 integrin subunit expression was analyzed in each cell line by flow cytometry (Table 2 ). In general, the ability of YESIK-VAVS to restore transduction capability to polymermodified virus in each cell line (Figure 5a and b) reflects the level of a6b1 integrin expression. Infection of PC-3 cells by YESIKVAVS-pcAdluc demonstrated the most significant increase in transduction efficiency compared with pcAdluc (Figure 5b ). PC-3 cells express high levels of a6 and b1 integrin subunits (both in terms of the percentage number of positive cells and mean fluorescence) ( Table 2 ) consistent with effective cell entry. In contrast, LNCaP cells lack high levels of either a6 or b1 integrin subunit expression and correspondingly failed to be transduced by YESIKVAVS-pcAdluc. The PNT1a and PNT-2 cells (immortalized normal prostate epithelium) demonstrated virtually no increase in transduction when polymer-coated viruses were retargeted. Both PNT1a and PNT2 cells expressed a6 and b1 integrins but at lower levels (in terms of mean fluorescence) than were detected on PC-3 cells. P4E6 cells, in terms of prostate cancer progression, fall between the immortalized normal cell lines (PNT1a and PNT2) and the metastatic PC-3 cells, being derived from a well-differentiated tumor. Correspondingly, the addition of YESIKVAVS to polymercoated virus had a slightly larger affect on P4E6 transduction than the immortalized normal cells but less than PC-3 cells (Figure 5b ). In contrast, the breast carcinoma cell line MCF-7 expressed low levels of both a6 and b1 integrin subunits (Table 2 ), but showed evidence of effective retargeting ( Figure 5 ). We would therefore conclude that other binding sites are available on breast carcinoma cells to mediate cell entry.
Effect of polymer modification and YESIKVAVS retargeting on biodistribution and plasma circulation
Finally, we performed in vivo studies in PC-3 subcutaneous tumor bearing MF-1 nude mice to examine biodistribution and the rate of plasma clearance. Intravenous administration of adenovirus results in rapid clearance from the blood by uptake mechanisms in the liver. 34, 35 To reduce nonspecific clearance by scavenging Kupffer cells, we treated mice with clodronate liposomes to transiently deplete the resident macrophages in liver and spleen. 36 2.5 Â 10 10 Adluc, pcAdluc or YESIKVAVSpcAdluc particles were administered by tail vein injection and blood samples taken at 2, 10 and 30 min after injection. The unmodified virus was rapidly cleared with less than 2% of the dose detected in the plasma at 2 min still present after 30 min (Figure 6a ). In contrast, polymer coating greatly reduced virus clearance with approximately 60% of pcAdluc detected at 2 min detectable after 30 min. The retention of pcAdluc in the circulation is an improvement on our earlier study using comparable doses 35 in which resident macrophages were not depleted, suggesting that much of the polymer-modified virus is cleared by nonspecific scavenger mechanisms. YESIKVAVSpcAdluc was cleared more rapidly than pcAdluc but less rapidly than unmodified virus, with 20% of the dose detected at 2 min still present in the plasma after 30 min. The addition of the targeting peptide has thus reduced the length of virus circulation mediated by polymer encapsulation.
We then compared the levels of transgene expression from YESIKVAVS-Adluc with Adluc and pcAdluc in liver, spleen, heart, lungs, kidneys and tumors after 48 h. Depletion of Kupffer cells removes the particle uptake mechanism in the liver resulting in hepatocyte transduction. [37] [38] [39] Following Adluc administration, the greatest luciferase expression was observed in the liver, which was 1700-fold higher than the tumor (Figure 6b) . In order to target tumors, it is therefore critical to detarget liver tropism. Polymer coating reduced liver expression 3400-fold (P ¼ 0.0145). Following retargeting with YESIKVAVS, expression levels in the liver remained over 300-fold lower than unmodified virus (P ¼ 0.0146). However, expression in the tumor from YESIKVAVS-pcAdluc was comparable with unmodified virus and nearly five-fold greater than polymer modified virus (although this was not significant because of high-level expression in one mouse). Consequently, the liver:tumor ratio decreased from 1700:1 for Adluc to o4:1 for YESIKVAVSpcAdluc. Importantly, the high level of virus toxicity shown by the release of ALT and AST into the blood stream from Adluc was completely absent following i.v. administration of YESIKVAVS-pcAdluc (Figure 6c) , consistent with decreased hepatocyte infection.
Discussion
The treatment of metastatic disease requires systemic therapies; our system of non-genetic adenovirus polymer modification having several advantages such as (i) prevention of native virus/cell interaction and uptake; (ii) provision of a framework for subsequent attachment of targeting moieties with tailor made interaction profiles and (iii) reduction of vector loss through pre-existing antibody neutralization. 26 A vector system specifically designed to target carcinoma cells will reduce side effects from inappropriate cytotoxic transgene expression in healthy tissue and reduce depletion of the vector pool permitting higher circulating virus titres. It is however necessary to identify potential specific target molecules that will mediate binding and uptake.
The a6b1/a6b4 integrin expression profile is altered during cancer progression. a6b1 integrin expression is maintained in prostate cancer, whereas a6b4 integrin expression is lost on carcinoma cells lacking hemidesmosomal structures. In contrast, b4 integrin expression is maintained in colon carcinomas and 60% of breast carcinomas. 15, 22 The loss of b4 integrin subunit expression leads to increased a6/b1 dimerization, 40 resulting in increased migratory and invasive properties. Correspondingly, the expression of a b4 integrin subunit cytoplasmic domain deletion mutant in hepatocellular carcinoma cells and highly invasive MDA-MB-435 melanoma cells knocked out a6b1 integrin expression, reducing cell adherence and migration on laminin and invasion of Matrigel. 20, 41 The interactions between cells and the ECM are complex with integrins functioning as receptors for laminins (reviewed in Belkin and Stepp 42 ) . Metastatic pancreatic cells can be prevented from adhering to purified laminin using anti-a6 and -b1-integrin subunit antibodies but not anti-b4 integrin antibodies. In addition, preincubation with anti-a6 and anti-b1-integrin subunit antibodies drastically reduced the numbers of metastases formed in the lungs of mice following tail vein injection. 10 The peptide sequence SIKVAV located within the E8 region of the laminin alpha-1 chain 23 promotes attachment, migration, angiogenesis, protease production, tumor growth and metastasis. [43] [44] [45] [46] [47] [48] [49] The adherence of primary bone marrow cultured mast cells and C57 mast cells to SIKVAV containing peptides, and the stimulation of uPA expression in macrophages by SIKVAV containing peptide, can both be blocked using anti-a6 integrin subunit antibdies. 24, 25 Consequently, SIKVAV mediated binding to the a6b1 integrin could offer discrimination between healthy and cancerous tissue for therapeutic viruses.
To investigate the potential of targeting polymer-coated adenovirus vectors to a6b1 integrins on prostate cells using the -SIKVAV-peptide, a range of cell lines were tested representing various stages of cancer progression ranging from the SV40T antigen immortalized normal epithelia (PNT1a and PNT2), [27] [28] [29] through the P4E6 cell line derived from a well-differentiated tumor, 30, 31 to the commonly used PC-3 and LNCaP lines derived from bone and supraclavicular lymph node metastases, respectively. Our analysis of the expression of the a6 and b1 integrin subunits in PC-3 and LNCaP cells was in agreement with previous studies, 13, 14 with the reduced a6 integrin expression on LNCaP cells reflected in their semiadherent growth pattern on laminin-coated surfaces.
Reaction of adenovirus with pHPMA-ONp greatly attenuated transduction of all cell lines tested with residual transgene expression mediated by virus entering owing to the incomplete abrogation of all fiber/CAR interactions. The addition of the PEGylated peptide YESIKVAVS to the polymer-coated virus restored infection of PC-3 cells, with removal of unincorporated polymer and peptide crucial for efficient transduction, presumably since free peptide competes with virus bound ligand for a6b1 integrin binding. Transduction capability was restored in the prostate lines in a manner that reflected the degree of a6b1 integrin expression. However, in the MCF-7 breast carcinoma cell line transduction was mediated by the peptide even though flow cytometric analysis indicated low levels of integrin expression. Consequently, we would conclude that SIKVAV can mediate interactions via other as yet unidentified receptors on these cell lines. To further confirm that SIKVAVretargeted viruses employ a6b1 receptors on target cells, studies that manipulate a6b1 levels by modifying integrin subunit expression, either by transient transfection of a6 and b1 integrin transgenes demonstrating increased virus uptake, or silencing of a6 and b1 integrins with siRNA demonstrating ablation of virus uptake are required. Importantly, the retargeted virus demonstrated no transduction above that of pc-Adluc, in the cells derived from normal prostate epithelia suggesting that the risk of inappropriate transgene expression in healthy tissue would be low. Although we detected b1 integrin subunits on both PNT1a and PNT2 cells in agreement with previous studies, 50, 51 we would expect these cells to maintain b4 integrin subunit expression to which the a6 subunit would preferentially dimerize, SIKVAV being unable to bind integrin a6b4. Summary of flow cytometric analysis using specific monoclonal anti-a6-integrin subunit and monoclonal anti-b1-integrin subunit antibodies on a panel of human cell lines. Data are shown as the percentage number of immunopositive cells, the mean fluorescence intensity (G Mean) and the relative expression level (area under the curve) determined by multiplying the fraction of positive cells by the mean fluorescent intensity.
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In vivo administration of the modified viruses to subcutaneous PC-3 tumor-bearing mice demonstrated that polymer coating greatly increased plasma circulation. Comparison with our previous data using non-clodronate treated mice 35 shows that more pc-Adluc is retained in the circulation when resident macrophages are transiently depleted confirming the nonspecific scavenger mechanism of polymer-coated virus particles. Retargeted virus was eliminated from the bloodstream more rapidly than pcAdluc, however, as we did not test the scrambled version of the peptide in our in vivo studies, we cannot determine whether nonspecific interactions account for some of these differences. Luciferase expression analysis revealed that SIKVAV can mediate transduction of target tumors and confirmed that the integrity of the modified virus was maintained. Importantly, transduction of the liver by YESIKVAV-pcAdluc was dramatically reduced compared with Adluc caused by the ablation of CAR mediated infection, resulting in the complete cessation of virus-induced toxicity as measured by ALT and AST release into the blood. The spleen, which can act as a secondary sink for administered adenovirus after the liver, was also effectively detargeted, and the low expression levels observed likely having been achieved by clodronate liposome depletion of splenocytes (resident macrophages). 36 Expression from pcAdluc was proportionally greater in the spleen compared with the liver possibly reflecting the increased circulation time and passive accumulation by physical filtration. Indeed, given the extended circulation times of pc-Adluc achievable by ablation of receptor-mediated infection, tumor accumulation from passive convective transport through leaky tumor vasculature may hold promise as an effective therapy. However, we believe retargeting will be required to seek out micrometastases that have not developed the leaky endothelial tumor vasculatures that would allow passive accumulation. Consequently, we believe that SIKVAV-bearing viruses have potential to deliver cytotoxic transgenes to a6b1 integrin expressing tumors for therapies to treat metastatic disease.
